Results 41 to 50 of about 15,200 (191)

Engineering tandem VHHs to target different epitopes to enhance antibody‐dependent cell‐mediated cytotoxicity

FEBS Open Bio, EarlyView.
Tandem VHH targeting distinct EGFR epitopes were engineered into a monovalent bispecific antibody (7D12‐EGA1‐Fc) with more potent ADCC without increasing affinity to EGFR. Structural modeling of 7D12‐EGA1‐Fc showed cross‐linking of separate EGFR domains to enhance CD16a engagement on NK cells.
Yuqiang Xu, Hao Jiang, Limin Chen, Fulai Zhou, Ying Jin, Mark L. Chiu   +5 more
wiley   +1 more source

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Haematologica, 2011
Background In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab.
Michael. S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, Tuna Mutis   +7 more
doaj   +1 more source

Clinical applications of personalized medicine: a new paradigm and challenge [PDF]

, 2017
The personalized medicine is an emergent and rapidly developing method of clinical practice that uses new technologies to provide decisions in regard to the prediction, prevention, diagnosis and treatment of disease.
Borro, Marina, DI SANZO, Mariantonia, Fineschi, Vittorio, Frati, Paola, LA RUSSA, Raffaele, Santurro, Alessandro, Scopetti, Matteo, Simmaco, Maurizio   +7 more
core   +1 more source

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma [PDF]

, 2023
Although treatment of multiple myeloma (MM) with daratumumab significantly extends the patient's lifespan, resistance to therapy is inevitable. ISB 1342 was designed to target MM cells from patients with relapsed/refractory MM (r/r MM) displaying lower ...
Berret, Jérémy, Blein, Stanislas, Borthakur, Gautam, Carretero-Iglesia, Laura, Chimen, Myriam, Doucey, Marie-Agnès, Drake, Adam, Edwards, Claire, Edwards, James, Estoppey, Carole, Gudi, Girish S, Kaya, Zeynep, Kervoëlen, Charlotte, Laurendon, Amélie, Macoin, Julie, Maiti, Abhishek, Matthes, Thomas, Mbow, M Lamine, Menon, Vinu, Menoret, Emmanuelle, Monney, Thierry, Moreau, Philippe, Nallet, Emilie, Pais Ferreira, Daniela, Pellat-Deceunynck, Catherine, Perro, Mario, Pihlgren, Maria, Pouleau, Blandine, Srivastava, Ankita, Suere, Perrine, Udupa, Venkatesha, Zhukovsky, Eugene   +31 more
core   +2 more sources

Daratumumab Treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): A Case Report

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune‐mediated neuropathy featuring progressive weakness, sensory deficits, and areflexia. While corticosteroids, intravenous immunoglobulin, and plasmapheresis are effective first‐line immunotherapies, a subset of patients remains treatment‐refractory.
Xueyu Zhang, Jianli Zhao, Xue Zhao, Xiaowei Hu, Zichun Xiao, Jie Wu, Xiaowen Li, Jing Xu, Yu‐Jing Li   +8 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

Nature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli, Tingjian Wang, Xiaoning Hong, Annamaria Gulla, Yu-Tzu Tai, Nikhil Munshi, Paul Richardson, Ruben Carrasco, Teru Hideshima, Kenneth C. Anderson   +21 more
doaj   +1 more source

Daratumumab in untreated newly diagnosed multiple myeloma

Therapeutic Advances in Hematology, 2019
The treatment of multiple myeloma has evolved markedly in the last decade, but mortality remains high, emphasizing the need for more effective therapies.
Nadine Abdallah, Shaji K. Kumar
doaj   +1 more source

Pulmonary tuberculosis infection and CMV reactivation following daratumumab treatment in a patient with relapsed plasmablastic lymphoma

Blood Science, 2022
Plasmablastic lymphoma (PBL) is an aggressive lymphoma with limited treatment strategies. Tuberculosis (TB) infection poses a high risk for patients with hematologic malignancies, especially those treated with immune agents but were never reported post ...
Wenyue Cao, Yuling Wan, Xingcheng Yang, Wei Huang, Jia Wei   +4 more
doaj   +1 more source

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma [PDF]

, 2020
Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to ...
Alegre, A, Balari, AS, Blanchard, MJ, Couturier, C, de la Rubia, J, Gaudig, M, Gonzalez, MS, Hevia, H, Insunza, A, Lleonart, JB, Mateos, MV, Milionis, I, Montero, LFC, Palomera, L, Pei, HL, Penarrubia, MJ, Potamianou, A, Rios-Tamayo, R, Rodriguez, CE, Rodriguez-Otero, P, Suarez, A   +20 more
core   +1 more source